The cell line carries both KRAS and TP53 gene mutations, which are ubiquitous driver-gene mutations in pancreatic cancer, and are responsible for the expression of tumor biomarkers, carcinoembryonic antigens, and carbohydrate antigens 19–9 (32, 33). This evidence concerns the gene KRAS and familial pancreatic carcinoma.